COMMUNIQUÉS West-GlobeNewswire

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

09/08/2024 - 17:00

WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically [...]

Neurotech Innovation Achieves Patent Approval and Featured Cover Story in Prominent Industry Journal

09/08/2024 - 15:00

-Prosthetic Cranial Implant Receives Patent, Elevates Neurosurgical Precision and Patient Outcomes- BALTIMORE, Md., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on [...]

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

09/08/2024 - 15:00

PALO ALTO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

09/08/2024 - 14:15

Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products [...]

Spectral Medical Announces Second Quarter Results and Provides Corporate Update

09/08/2024 - 14:00

Tigris Trial Enrollment Reaches 126 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “ [...]

NeurAxis Reports Second Quarter 2024 Financial Results

09/08/2024 - 14:00

Conference call will be held today, Friday, August 9 at 9:00 am ET Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]

Elucent Medical Announces Froedtert & the Medical College of Wisconsin Health Network to Provide New Breast Cancer Surgical Technology

09/08/2024 - 14:00

EDEN PRAIRIE, Minn., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of guided surgical technology, is thrilled to announce Froedtert & the Medical [...]

Sofwave to Participate in 9th Annual Needham Virtual MedTech & Diagnostics Conference

09/08/2024 - 14:00

SAN CLEMENTE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, [...]

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

09/08/2024 - 14:00

Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 WILMETTE, Ill., Aug. 09, 2024 ( [...]

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

09/08/2024 - 14:00

WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it [...]

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

09/08/2024 - 14:00

Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on [...]

MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent

09/08/2024 - 14:00

VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the " Company " or " MedBright AI ") (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Christopher Heath has [...]

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15

09/08/2024 - 14:00

MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in [...]

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 13:30

BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

09/08/2024 - 13:00

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09/08/2024 - 13:00

$426.4M cash, cash equivalents and marketable securities as of June 30, 2024; Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical- [...]

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09/08/2024 - 13:00

-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL [...]

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

09/08/2024 - 13:00

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic [...]

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09/08/2024 - 13:00

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million MHRA and Health Canada approved CARVYKTI ® in earlier lines of treatment for adult patients with relapsed and lenalidomide- [...]